

# **CLINICAL TRIALS WATCH**

**ACCESSIBLE EASY READ INFORMATION ON:**

**Cognitive training STUDY**

# Cognitive training study

<b>1. Study Information</b>	
<b>Name of the study</b>	Can a serious game-based cognitive training attenuate cognitive decline related to Alzheimer's disease?
<b>Study sponsor</b>	University of Bern
<b>Disease</b>	Alzheimer's disease, dementia, mild cognitive impairment
<b>Phase</b>	Not applicable – cognitive training

<b>2. Information about the intervention that will be tested in the study</b>	
<b>Name of the intervention</b>	Computerised cognitive training
<b>Administration</b>	Tablet-based cognitive training game, targeting the cognitive domains mostly affected by Alzheimer's disease, daily for 20 minutes.
<b>Will all participants receive the same intervention?</b>	<p>Participants will be selected at random to either receive one of the following options:</p> <ul style="list-style-type: none"><li>• Computerised cognitive training for three months at home with weekly on-site group meetings, then six months at home with monthly on-site group meetings</li><li>• Watch documentaries for three months at home, then do computerised cognitive training for three months at home (active control group)</li><li>• Computerised cognitive training with a delay of three months (wait-list control group).</li></ul>

<b>3. Information about participating in the study</b>	
<b>What are the researchers trying to find out?</b>	<ul style="list-style-type: none"><li>• The purpose of the study is to evaluate if computerised-cognitive training is able to attenuate cognitive decline related to Alzheimer's disease.</li></ul>
<b>How long will the study last?</b>	<ul style="list-style-type: none"><li>• 9 months</li></ul>
<b>What your involvement will entail?</b>	<ul style="list-style-type: none"><li>• Participants will be asked to complete some tests to access memory, verbal fluency and visuospatial abilities</li></ul>

	<ul style="list-style-type: none"> <li>• Participants will be also requested to complete brain scan (MRI).</li> </ul> <p>Further information on the procedures, tests and visits can be obtained from the study team.</p>
--	---

#### 4. Who can participate in this study?

<b>Who can participate in the study?</b>	<p>To take part in the study, participants must:</p> <ul style="list-style-type: none"> <li>• Be 60 to 85 years old</li> <li>• Have a clinical diagnosis of Alzheimer's disease</li> <li>• Be at increased risk for developing dementia.</li> </ul>
<b>Who cannot participate in the study?</b>	<p>Exclusion criteria include:</p> <ul style="list-style-type: none"> <li>• Contraindications for brain scans (MRI)</li> <li>• Substance abuse</li> <li>• Severe medical conditions.</li> </ul> <p>The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study.</p>

#### 5. Where and when will the study be conducted?

<b>European country involved in the trial</b>	<ul style="list-style-type: none"> <li>• Switzerland</li> </ul>
<b>Estimated start date of recruitment</b>	July 2020

<b>6. Information for your doctor</b>	
<b>Clinicaltrials.gov identifier</b>	NCT04452864
<b>Study contact information</b>	Esther Brill - <a href="mailto:esther.brill@upd.unibe.ch">esther.brill@upd.unibe.ch</a>  Christine Krebs - <a href="mailto:christine.krebs@upd.unibe.ch">christine.krebs@upd.unibe.ch</a>
<b>Link to full text</b>	<a href="https://clinicaltrials.gov/ct2/show/NCT04452864">https://clinicaltrials.gov/ct2/show/NCT04452864</a>

- ✓ The information contained in this document is based on information available on public registries (e.g. clinicaltrials.gov website) on January 2023.